Compass Therapeutics Q2 net loss widens to $19.9 mln

Compass Therapeutics

11/08/2025 12:11

Overview

Compass Q2 net loss widens to $19.9 mln from $13.1 mln last year

Company ends Q2 with $101 mln cash, runway into 2027

Tovecimig shows fewer deaths than projected in Phase 2/3 study

Outlook

Company expects tovecimig secondary endpoint analysis in Q1 2026

Compass plans CTX-8371 cohort expansions in Q4 2025

Company to file IND for CTX-10726 in Q4 2025

Compass anticipates cash runway into 2027

Result Drivers

G&A - Increased by 20%, primarily due to $1.6 million in additional share-based compensation expense

R&D - Expenses were $16.4 million for the quarter ended June 30, 2025, as compared to $11.2 million for the same period in 2024, an increase of $5.2 million, or 47%.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$19.88 mln
Q2 Basic EPS
-$0.14
Q2 Income From Operations
-$21.07 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $9.50, about 71.6% above its August 8 closing price of $2.70

Press Release: ID:nGNXwsLW3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)